Shufti Establishes a New Standard for VideoIdent Solutions in the DACH Region
Shufti Sets a New Benchmark for VideoIdent in the DACH Market Shufti, a global identity verification and compliance technology provider announced the expansion of its VideoIdent solution across Germany, Austria, and Switzerland…
Merck and Mayo Clinic Partner to Advance AI-Driven Drug Discovery and Precision Medicine
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine Merck known as MSD outside of the U.S. and Canada, and Mayo Clinic,…
ENHERTU® Variation Application Accepted in EU for Post-Neoadjuvant Use in Early HER2-Positive Breast Cancer
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation…
Affinia Therapeutics Receives EMA Orphan Designation for Gene Therapy AFTX-201 in BAG3 Cardiomyopathy
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class…
ChartCheck Adaptive Deployment Expands Across Australia with Icon Group After FDA 510(k) Clearance
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated…
Spruce Biosciences Advances TA-ERT Program Following Constructive Type B Discussions with U.S. FDA
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on…
KalVista’s EKTERLY® Added as First-Line Treatment for Patients Aged 12+ in Pediatric HAE Guideline
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published…
Korsana Biosciences Launches with $175 Million to Develop Innovative Neurodegenerative Treatments
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to…
GenSight Biologics Expands Regulatory Team Across the U.S. and Europe
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments GenSight Biologics a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases…
New Study Highlights Flashpoint Therapeutics’ Breakthrough HPV Cancer Vaccine
Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the…
Janux Therapeutics Doses First Patient in Phase 1 Trial of JANX011
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the…
Twist Bioscience Broadens Antibody Discovery Portfolio Through New Bispecific Licensing Deal
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement Twist Bioscience Corporation a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement…